Global Clinical Next-Generation Sequencing (NSG) Testing Market, By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-time Sequencing, Nano Pore Sequencing and Other Sequencing Technologies), Application (Diagnostics, Drug Discovery, Agricultural and Animal Research and Other Applications), End User (Academic Institutes and Research Centres, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Other End Users), Service (Human Genome Sequencing, Single Cell Sequencing, Microbial Genome-based Sequencing, Gene Regulation Services, Animal and Plant Sequencing and Other Sequencing Services), Workflow (Pre-Sequencing, Sequencing and Data Analysis), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Technological advancements in the clinical next-generation sequencing (NSG) testing coupled with rising research and development proficiencies are fostering the market growth. Data Bridge Market Research analyses that the clinical next-generation sequencing (NSG) testing market will exhibit a CAGR of around 27.25% for the forecast period of 2021-2028.
Clinical next-generation sequencing (NSG) testing is a testing that has put genomic sequencing into clinical practice. The clinical next-generation sequencing (NSG) testing allows the doctors or clinicians to test and monitor the genes. It helps in detecting and identifying the order of adenine, guanine, cytosine, and thymine. This technology helps in identifying the cause within a reduced time frame thus improving the efficiency of healthcare practices.
Increasing awareness about the benefits of clinical next-generation sequencing (NSG) testing technology has bolstered the growth in its demand. The growth and expansion of the genomics industry across the globe are also fostering the growth of clinical next-generation sequencing (NSG) testing technology. Rising governmental research and developmental initiatives will further widen the scope of market growth.
However, problems in data analytics while performing single-cell sequencing will slow down the market growth. A low-grade technological base especially in the underdeveloped economies will further hammer down the growth rate of the market. Difficulty in the management of large and composite data will also pose a challenge to the market.
This clinical next-generation sequencing (NSG) testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on clinical next-generation sequencing (NSG) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Clinical Next-Generation Sequencing (NSG) Testing Market Scope and Market Size
The clinical next-generation sequencing (NSG) testing market is segmented on the basis of technology, application, end user, service and workflow. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of technology, the clinical next-generation sequencing (NSG) testing market is segmented into sequencing by synthesis, ion semiconductor sequencing, single- molecule real-time sequencing, Nano pore sequencing and other sequencing technologies.
- On the basis of application, the clinical next-generation sequencing (NSG) testing market is segmented into diagnostics, drug discovery, agricultural and animal research and other applications. Diagnostics is further sub-segmented into cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics and other diagnostic applications.
- On the basis of end user, the clinical next-generation sequencing (NSG) testing market is segmented into academic institutes and research centres, hospitals and clinics, pharmaceutical and biotechnology companies and other end users.
- The clinical next-generation sequencing (NSG) testing market is also segmented on the basis of service into human genome sequencing, single cell sequencing, microbial genome- based sequencing, gene regulation services, animal and plant sequencing and other sequencing services.
- On the basis of workflow, the clinical next-generation sequencing (NSG) testing market is segmented into pre-sequencing, sequencing and data analysis.
Clinical Next-Generation Sequencing (NSG) Testing Market Country Level Analysis
The clinical next-generation sequencing (NSG) testing market is analysed and market size insights and trends are provided by country, technology, application, end user, service and workflow as referenced above.
The countries covered in the clinical next-generation sequencing (NSG) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the clinical next-generation sequencing (NSG) testing market. The presence of major key players using clinical next-generation sequencing (NSG) testing technology is driving the growth of the market in this region. Asia-Pacific on the other hand will project the highest growth rate during the forecast period owing to the rising government initiatives to boost up the genomics industry.
The country section of the clinical next-generation sequencing (NSG) testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Clinical Next-Generation Sequencing (NSG) Testing Market Share Analysis
The clinical next-generation sequencing (NSG) testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to clinical next-generation sequencing (NSG) testing market.
The major players covered in the clinical next-generation sequencing (NSG) testing market report are 3billion, Inc., 10x Genomics., 23andMe, Inc., Adaptive Biotechnologies., Admera Health, Agilent Technologies, Inc., ALCEN, Almac Group, AMARANTUS BIOSCIENCE HOLDINGS, INC., Ambry Genetics., Aperiomics, Inc., ARUP Laboratories., ASURAGEN, INC., Athena Diagnostics, Inc., Atreca, Inc., Base4, Baylor Genetics, BD, Berry Gene, BGI, Bioarray S.L, Biodesix., Boreal Genomics Inc. and Cambridge Epigenetix Limited among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Clinical Next-Generation Sequencing (NSG) Testing Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.